Tagi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAGI, and what generic and branded alternatives to TAGI drugs are available?
TAGI has four approved drugs.
Drugs and US Patents for Tagi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tagi | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 215615-002 | Oct 18, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Tagi | CHOLESTYRAMINE | cholestyramine | POWDER;ORAL | 209597-002 | Mar 9, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Tagi | CHOLESTYRAMINE LIGHT | cholestyramine | POWDER;ORAL | 209599-002 | Nov 12, 2020 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Tagi | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212857-003 | Nov 23, 2020 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Tagi | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 215615-001 | Oct 18, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Tagi | CHOLESTYRAMINE | cholestyramine | POWDER;ORAL | 209597-001 | Mar 9, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.